Boundless Bio intends to use the funds advancing BBI-355 for patients with oncogene-amplified cancer. Credit: NIH Image Gallery /Flickr (Creative Commons).

Precision oncology company Boundless Bio has raised $100m in a Series C financing round for advancing extrachromosomal DNA (ecDNA)-directed therapies for oncogene-amplified cancer patients.

Co-led by Leaps by Bayer and RA Capital Management, the Series C round saw the participation from new investors Piper Heartland Healthcare Capital and Sectoral Asset Management.

Go deeper with GlobalData

Data Insights

The gold standard of business intelligence.

Find out more

Related Company Profiles

View all

Existing investors, including PFM Health Sciences, Nextech Invest, Logos Capital, Wellington Management, and Vertex Ventures HC, also participated in the Series C financing.

Boundless Bio intends to use the funds for the initial clinical development of the first ecDNA-directed therapy (ecDTx), BBI-355, through clinical data readouts from its ongoing Phase I/II POTENTIATE clinical trial.

An oral, potentially best-in-class checkpoint kinase 1 (CHK1) inhibitor, BBI-355 demonstrated preclinically to be synthetically lethal to ecDNA-bearing oncogene-amplified cancer cells.

The proceeds from the financing round will also be used for advancing the company’s differentiated ecDTx candidates’ preclinical pipeline.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

The funds will also support the advancement of Boundless Bio’s ECHO (ecDNA Harboring Oncogenes), an ecDNA diagnostic clinical trial assay.

The company is developing the assay with Sophia Genetics.

Boundless Bio president and CEO Zachary Hornby said: “The support from new investors along with the continued commitment of our existing investors emphasises our momentum and progress in bringing the first ecDNA-directed therapies to patients with oncogene-amplified cancers.”

The company also announced that Leaps by Bayer venture investments health senior director Fabio Pucci will join its board of directors.